arXivDaily arXiv每日学术速递 周一至周五更新
arXiv周末暂无论文更新,休息一下吧,周末愉快~~
arXiv 2602.17984stat.ME
收藏

在实际约束下开发具有性能保证的生物标志物组合规则,整合外部信息

Developing Performance-Guaranteed Biomarker Combination Rules with Integrated External Information under Practical Constraint

University of Washington(华盛顿大学);Fred Hutchinson Cancer Center(弗雷德·哈钦森癌症中心);Kelsey Research Foundation(凯利研究基金会);University of Texas MD Anderson Cancer Center(德州大学安德森癌症中心)

Albert Osom, Camden Lopez, Ashley Alexander, Suresh Chari, Ziding Feng, Ying-Qi Zhao

AI总结:

本文提出了一种在实际约束下整合外部信息的生物标志物决策规则开发框架,通过最大化真阳性率并满足阳性预测值约束,提升早期疾病检测的临床实用性与性能。

摘要:

在临床实践中,整合新型生物标志物与现有临床数据以构建可解释且稳健的决策规则存在显著兴趣。受早期疾病检测决策改进的启发,我们提出了一种开发最优生物标志物基于临床决策规则的框架,该规则在临床有意义且在实践中可行。具体而言,我们的程序构建了一个线性决策规则,旨在在线性规则类别中实现最优性能,通过最大化真阳性率同时遵守预设的阳性预测值约束。此外,我们的方法可以自适应地整合来自外部来源的个体风险信息,以增强性能,当此类信息有益时。我们建立了所提出估计器的渐近性质,并通过广泛的模拟研究与实践中使用的标准方法进行比较。结果表明,我们的方法在有限样本性能方面表现强劲。我们还应用所提出的方法,为新发糖尿病(NOD)患者开发生物标志物基于的筛查规则,用于胰腺导管腺癌(PDAC)的检测。

英文摘要:

In clinical practice, there is significant interest in integrating novel biomarkers with existing clinical data to construct interpretable and robust decision rules. Motivated by the need to improve decision-making for early disease detection, we propose a framework for developing an optimal biomarker-based clinical decision rule that is both clinically meaningful and practically feasible. Specifically, our procedure constructs a linear decision rule designed to achieve optimal performance among class of linear rules by maximizing the true positive rate while adhering to a pre-specified positive predictive value constraint. Additionally, our method can adaptively incorporate individual risk information from external source to enhance performance when such information is beneficial. We establish the asymptotic properties of our proposed estimator and compare to the standard approach used in practice through extensive simulation studies. Results indicate that our approach offers strong finite-sample performance. We also apply the proposed methods to develop biomarker-based screening rules for pancreatic ductal adenocarcinoma (PDAC) among new-onset diabetes (NOD) patients.

机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。

↑